Haemonetics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Haemonetics and other ETFs, options, and stocks.

About HAE

Haemonetics Corp. engages in the development and distribution of hematology products and solutions. It operates through the following segments: Plasma, Blood Center, and Hospital. 

CEO
Christopher A. Simon
CEOChristopher A. Simon
Employees
3,009
Employees3,009
Headquarters
Boston, Massachusetts
HeadquartersBoston, Massachusetts
Founded
1971
Founded1971
Employees
3,009
Employees3,009

HAE Key Statistics

Market cap
3.09B
Market cap3.09B
Price-Earnings ratio
33.00
Price-Earnings ratio33.00
Dividend yield
Dividend yield
Average volume
949.72K
Average volume949.72K
High today
$68.22
High today$68.22
Low today
$66.19
Low today$66.19
Open price
$66.19
Open price$66.19
Volume
911.43K
Volume911.43K
52 Week high
$87.32
52 Week high$87.32
52 Week low
$47.32
52 Week low$47.32

Stock Snapshot

Haemonetics(HAE) stock is priced at $67.81, giving the company a market capitalization of 3.09B. It carries a P/E multiple of 33.00.

During the trading session on 2026-05-31, Haemonetics(HAE) shares reached a daily high of $68.22 and a low of $66.19. At a current price of $67.81, the stock is +2.4% higher than the low and still -0.6% under the high.

Trading volume for Haemonetics(HAE) stock has reached 911.43K, versus its average volume of 949.72K.

Over the past 52 weeks, Haemonetics(HAE) stock has traded between a high of $87.32 and a low of $47.32.

Over the past 52 weeks, Haemonetics(HAE) stock has traded between a high of $87.32 and a low of $47.32.

HAE News

TipRanks 3d
Haemonetics price target raised to $70 from $64 at Citi

Citi raised the firm’s price target on Haemonetics (HAE) to $70 from $64 and keeps a Neutral rating on the shares. The firm updated models in the medical techno...

Simply Wall St 4d
Haemonetics' Conservative Accounting Might Explain Soft Earnings

The market for Haemonetics Corporation's ( ) shares didn't move much after it posted weak earnings recently. We think that the softer headline numbers might be...

Haemonetics' Conservative Accounting Might Explain Soft Earnings

Analyst ratings

73%

of 11 ratings
Buy
72.7%
Hold
27.3%
Sell
0%

People also own

Based on the portfolios of people who own HAE. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.